SEC Form 4 · accession 0001179110-17-003930
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Bisaro
Director
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 6:59 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1 | Mar 2, 2017 | S | 31,674 | $245.73 | D | 274,226 | D | |
| Ordinary Shares, par value $0.0001F2 | Mar 2, 2017 | S | 8,267 | $246.64 | D | 265,959 | D | |
| Ordinary Shares, par value $0.0001F3 | Mar 2, 2017 | S | 27,688 | $247.63 | D | 238,271 | D | |
| Ordinary Shares, par value $0.0001F4,F5 | Mar 2, 2017 | S | 2,371 | $248.40 | D | 235,900 | D | |
| Ordinary Shares, par value $0.0001 | holding | — | — | — | 120,000 | I | Paul Bisaro LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $245.21 to $246.17, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $246.21 to $247.02, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $247.22 to $248.21, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $248.33 to $248.45, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- F5Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.